SCHEMBL3540201

SCHEMBL3540201

COC(=O)c1cccc(C)c1CBr

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
NR4A2 P43354 1/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 2/20 0.44
CFTR P13569 1/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 5/20 0.43
MAPT P10636 3/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
POLB P06746 3/20 0.43
ATM Q13315 1/20 0.43
MYC P01106 1/20 0.42
GLA P06280 1/20 0.41
ALOX12 P18054 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29041518 0.89 LMNA (0.52) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL20577090 0.86 PLK1 (0.39) ALDH1A1L3MBTL1HTTTSHRHSD17B10
SCHEMBL6354255 0.85 TSHR (0.59) ALDH1A1TSHRHSD17B10KMT2AMAPT
SCHEMBL7870569 0.84 ALDH1A1 (0.48) ALDH1A1L3MBTL1HTTNR4A2LMNA
SCHEMBL6534556 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTNR4A2LMNA
SCHEMBL17424944 0.83 LMNA (0.59) ALDH1A1LMNATSHRHSD17B10CFTR
SCHEMBL12174317 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTNR4A2LMNA
SCHEMBL4739763 0.83 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTNR4A2LMNA
SCHEMBL30041782 0.83 LMNA (0.46) ALDH1A1HTTLMNATSHRHSD17B10
SCHEMBL5839700 0.83 ALDH1A1 (0.53) ALDH1A1L3MBTL1HTTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
WO-2021126973-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. (US) 2021-06-24 WO disclosed
WO-2014066490-A1 BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME CORP. (US) 2014-05-01 WO disclosed
US-7820697-B2 Compositions and method for reducing TNFα levels CELGENE CORPORATION (US) 2010-10-26 US disclosed
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-25 US disclosed
US-20080287496-A1 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels CELGENE CORPORATION 2008-11-20 US disclosed
EP-0983064-B1 PYRROLES AS sPLA2 INHIBITORS LILLY CO ELI (US) 2003-08-06 EP disclosed
US-20030028028-A1 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels CELGENE CORPORATION 2003-02-06 US disclosed
US-6403613-B1 ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) CELGENE CORPORATION 2002-06-11 US disclosed
US-20010006973-A1 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS MAN HON-WAH (US) 2001-07-05 US disclosed
EP-0983064-A4 PYRROLES AS sPLA2 INHIBITORS LILLY CO ELI (US) 2001-01-31 EP disclosed
EP-1064277-A1 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES Gelgene Corporation (US) 2001-01-03 EP disclosed
EP-0983064-A1 PYRROLES AS sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2000-03-08 EP disclosed
WO-1999047512-A1 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES COLGENE CORPORATION (US) 1999-09-23 WO disclosed
US-5919774-A NOVEL COMPOUNDS SUCH AS 2-(1-BENZYL-2,5-DIMETHYL-4-(2-CARBOXYPHENYLMETHYL)PYRROL-3-YL) GLYOXAMIDE FOR INHIBITING HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE A2 (SPLA2) MEDIATED RELEASE OF FATTY ACIDS IN A MAMMAL ELI LILLY AND COMPANY (US) 1999-07-06 US disclosed
WO-1998025609-A1 PYRROLES AS sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1998-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms CRBN, CD4, CD74 ALDH1A1 4395/4885L3MBTL1 3246/4885HTT 2151/4885
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN ALDH1A1 798/4885L3MBTL1 2898/4885HTT 2521/4885
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 ALDH1A1 2539/4885L3MBTL1 480/4885HTT 916/4885
US-20080287496-A1 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels IL1A, IL1B, TNF ALDH1A1 139/4885L3MBTL1 1241/4885HTT 3597/4885
US-20010006973-A1 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS TNF, IL1A, IL1B ALDH1A1 171/4885L3MBTL1 1253/4885HTT 3640/4885
US-20030028028-A1 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels TNF, IL1A, IL1B ALDH1A1 171/4885L3MBTL1 1253/4885HTT 3640/4885
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABL1, LCK, MAP3K7 ALDH1A1 2410/4885L3MBTL1 3814/4885HTT 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.